Headache, Migraine Clinical Trial
— UNIONOfficial title:
Ubrogepant Efficacy and Safety in the Treatment of Acute Migraine in Patients Currently Treated With CGRP Monoclonal Antibodies (CGRPmAbs)
This is a prospective open-label randomized study assessing similar endpoints included in the pivotal trial for ubrogepant, which are pain freedom and freedom from the most bothersome symptom at two hours. Patients between 18-75 years old with a one-year history of migraine who experience ≥3 migraine days/month will be screened. This study will include migraine patients treated with or without injectable CGRPmAbs. As was the case in the clinical trials, this will be a single-attack study. Patients will be randomized to treat a single migraine attack with ubrogepant 50mg or 100mg. Patients will record dosing time, most bothersome symptom (nausea, photophobia, or phonophobia - chosen by patient), pain freedom, pain relief, the use of a 2nd dose if required, and adverse reactions. Patients will follow up within 30 days post treatment. Patients will be assessed for adverse events, and the safety data will be compared with the original clinical trial.
Status | Recruiting |
Enrollment | 164 |
Est. completion date | September 2024 |
Est. primary completion date | May 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Male or female patients ages 18 to 75 years, at screening (Visit 1). - At least a 1-year history of migraine with or without aura. - History of =3 monthly headache days of at least moderate severity. - Study patient currently on CGRPmAbs must be on treatment > 1 month at screening. - By history, the patient's migraines typically last between 4 and 72 hours if untreated or treated unsuccessfully and migraine episodes are separated by at least 48 hours of headache pain freedom Exclusion Criteria: - History of <3 monthly headache days of at least moderate severity - Concomitant use of strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. John's Wort) - Concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) - Currently on Botox treatment for CM. - Concomitant use of gepants as a preventative treatment. - Current user of illicit drugs, or a history within 1 year prior to screening (visit 1) of drug or alcohol abuse or dependence - Clinically significant hematologic, endocrine, cardiovascular, pulmonary, gastrointestinal, or neurologic disease. If there is a history of such a disease, but the condition has been stable for more than 1 year prior to screening (visit 1) and is judged by the PI as not likely to interfere with participation in the study, the participant may be included. - Woman is pregnant, planning to become pregnant during the course of the study, or currently lactating. |
Country | Name | City | State |
---|---|---|---|
United States | Chicago Headache Center & Research Institute | Chicago | Illinois |
United States | Chicago Headache Center & Research Institute | Naperville | Illinois |
Lead Sponsor | Collaborator |
---|---|
Chicago Headache Center & Research Institute | AbbVie |
United States,
Dodick DW, Lipton RB, Ailani J, Halker Singh RB, Shewale AR, Zhao S, Trugman JM, Yu SY, Viswanathan HN. Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II. Headache. 2020 Apr;60(4):686-700. doi: 10.1111/head.13766. Epub 2020 Feb 19. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pain freedom | Pain freedom at 2 hours. | 2 hours post treatment | |
Primary | Freedom from most bothersome symptom | Freedom from most bothersome symptom at 2 hours. | 2 hours post treatment | |
Secondary | Pain relief at 2 hours | Pain relief at 2 hours (this is different from pain freedom: moderate to severe pain reduced to mild or no pain). | 2 hours post treatment | |
Secondary | Percentage of patients with sustained pain relief from 2-24 hours after initial dose. | Percentage of patients with sustained pain relief from 2-24 hours after initial dose. | 2-24 hours after initial dose | |
Secondary | Percentage of patients with sustained pain freedom from 2-24 hours after initial dose. | Percentage of patients with sustained pain freedom from 2-24 hours after initial dose. | 2-24 hours after initial dose | |
Secondary | Pain relief at 2 hours after 2nd dose | Pain relief at 2 hours after 2nd dose. | 2 hours after 2nd dose | |
Secondary | Percentage of patients with sustained pain relief from 2-24 hours after 2nd dose. | Percentage of patients with sustained pain relief from 2-24 hours after 2nd dose. | 2-24 hours after 2nd dose | |
Secondary | Percentage of patients with sustained pain freedom from 2-24 hours after 2nd dose. | Percentage of patients with sustained pain freedom from 2-24 hours after 2nd dose. | 2-24 hours after 2nd dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04905654 -
Migraine Inducing Effect of Levcromakalim in Patients With Migraine With Aura
|
N/A | |
Completed |
NCT04111484 -
Adrenomedullin Effect on Migraine Without Patients
|
N/A | |
Recruiting |
NCT04091789 -
Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea
|
Phase 2 | |
Completed |
NCT03337620 -
Efficacy and Safety of Tx360® Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine
|
Phase 3 | |
Completed |
NCT02259387 -
Adolescents With Migraine: What's Stress Got To Do With It?
|
||
Completed |
NCT05658185 -
Migraine Difficult to Treat: the Importance of Psychological Care in the Chronic Patient
|
N/A | |
Completed |
NCT05001399 -
Feasibility of Using Holographic Memory Resolution® (HMR) in Patients/Clients With Pain
|
N/A | |
Completed |
NCT03490500 -
Using the S100B Protein for Emergency Headache Management Care (S100)
|
||
Completed |
NCT03075020 -
Carbon Monoxide Migraine-inducing Effects in Patients With Migraine Without Aura.
|
N/A | |
Recruiting |
NCT03472092 -
Mind and Body Approaches to Pain Reduction in Youth With Migraine
|
Phase 2 | |
Enrolling by invitation |
NCT04976985 -
Osteopathic Manipulative Treatment and Migraine Headaches
|
N/A | |
Active, not recruiting |
NCT04372264 -
Intravenous Paracetamol, Dexketoprofen and Ibuprofen in the Treatment of Acute Migraine Attack Headache
|
Phase 4 | |
Recruiting |
NCT04623203 -
The Prognosis of Migraine and Tension-Type Headache in Children and Adolescents
|
||
Completed |
NCT04577443 -
The Effect of Adenosine on Cranial Hemodynamic, Headache and Migraine Induction Properties.
|
N/A | |
Completed |
NCT03560024 -
The Effect of PACAP27 on the Extra- and Intracerebral Arteries Assessed by Magnetic Resonance Angiography (MRA) on Healthy Volunteers
|
N/A | |
Completed |
NCT03228355 -
Headache Inducing Effect of Cromakalim in Migraine Patients
|
N/A | |
Completed |
NCT02438553 -
Short-term Effectiveness of Transcutaneous Nerve Stimulation in Reducing Migraine Related Pain
|
N/A | |
Recruiting |
NCT03577548 -
Influence of Main Psychological and Social Factors on Primary Headaches
|
||
Recruiting |
NCT04715685 -
Mind Body Balance for Pediatric Migraine
|
N/A | |
Completed |
NCT05853900 -
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine
|
Phase 3 |